Millennium Management Llc Buys 6,005 Shares of Sensei Biotherapeutics (NASDAQ:SNSE) Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc purchased 6,005 shares of Sensei Biotherapeutics stock in a transaction that occurred on Tuesday, March 31st. The stock was purchased at an average price of $28.16 per share, with a total value of $169,100.80. Following the transaction, the insider owned 146,657 shares in the company, valued at $4,129,861.12. This represents a 4.27% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $28.12, for a total transaction of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total transaction of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total transaction of $23,629.68.
• On Monday, March 30th, Millennium Management Llc purchased 9,533 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $25.86 per share, with a total value of $246,523.38.
• On Friday, March 27th, Millennium Management Llc purchased 15,321 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $26.61 per share, with a total value of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc purchased 5,731 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $28.62 per share, with a total value of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total transaction of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total transaction of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc purchased 6,175 shares of Sensei Biotherapeutics stock. The stock was purchased at an average price of $34.49 per share, with a total value of $212,975.75.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $32.12, for a total transaction of $246,231.92.

Sensei Biotherapeutics Stock Performance

Sensei Biotherapeutics stock opened at $20.43 on Friday. The firm has a market cap of $27.38 million, a PE ratio of -0.14 and a beta of -0.18. The firm’s 50 day moving average price is $28.89 and its two-hundred day moving average price is $17.87. Sensei Biotherapeutics, Inc. has a twelve month low of $5.25 and a twelve month high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($130.83). Equities analysts anticipate that Sensei Biotherapeutics, Inc. will post -2.77 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC boosted its position in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,516 shares of the company’s stock after buying an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. 10.50% of the stock is owned by institutional investors.

More Sensei Biotherapeutics News

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Analysts Set New Price Targets

Several research analysts have weighed in on SNSE shares. Wall Street Zen lowered shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Finally, Leerink Partners started coverage on shares of Sensei Biotherapeutics in a research note on Monday, April 20th. They issued an “outperform” rating and a $50.00 price objective on the stock. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $40.00.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.